Daniel Troy, chief counsel of the FDA and the Food and Drug Division of the FDAs Office of General Counsel has resigned. Troy will be succeded by the FDA's current deputy general counsel, Jerry Masoudi who will become acting chief counsel until a permanent replacement is appointed. The announcement was made in a memorandum to FDA staff from Lester Crawford, the agency's acting commissioner. "Dan has served the agency with tireless dedication," Crawford wrote. Troy joined the FDA in August 2001, and soon after assisted the FDA is addressing myriad public health dimensions of the terrorist attacks of Sept. 11, 2001 and the soon-to-follow anthrax attacks. He went on to initiate reforms to the Hatch-Waxman amendments to the Federal Food, Drug and Cosmetic Act, estimated to save consumers over $35 billion over ten years. According to published reports, Troy had no immediate plans for future employment. Government rules stipulate he is forbidden from appearaing before the FDA, through legal briefs or on behalf of a client, for one year.